

## Bioshares Holiday Period Editions

Tuesday 24 December  
Thursday 2 January  
Tuesday 28 January

Bioshares is published 48 times a year

Companies covered: ANP, PXS

This Special Edition of *Bioshares* provides analysis of Antisense Therapeutics, which has released the final results of its Phase IIa study of ATL1102 in Duchenne's Muscular Dystrophy, and Pharmaxis, which announced that Boehringer Ingelheim will discontinue the development of BI 1467335 (formerly PXS 4728A) in the indication of NASH, but is continuing with its development in diabetic retinopathy.

# Bioshares

18 December 2019  
Edition 824

*Delivering independent investment research to investors on Australian  
biotech, pharma and healthcare companies*

Extract from *Bioshares* –

## **Antisense Therapeutics to Move into Phase IIb with Positive Phase II Data**

Antisense Therapeutics (ANP: \$0.086) has released data from the full nine patients in its Phase IIa Duchenne Muscular Dystrophy (DMD) study with ATL1102 with clear positive indicators which support moving the program into a Phase IIb study.

That Phase IIb study will be conducted in Europe, and pending the quality of the results, may become a pivotal study which would allow for registration of the therapy. A Phase IIb study would likely involve 80 children with DMD who are non-ambulant (in wheelchairs) and should start next year. Patients are likely to be treated for 12 months with ATL1102 and we expect it to take two years to generate results.

ATL1102 is an antisense drug compound. It inhibits CD49d present on T cells and it has been found that children with DMD with higher levels of CD49d progress more rapidly with the disease. Inhibiting CD49d is thought to lower the level of inflammation that contributes to the deterioration in muscle growth and function that characterises this disease. Antisense Therapeutics has previously shown in a Phase II study that CD49d levels can be reduced in patients with multiple sclerosis and control the disease at a much higher dose of 400mg a week, however there are some side effect concerns at higher doses.

In this children's study, a dose of 25mg per week was evaluated with no safety issues. The Phase IIb study is likely to explore higher doses of the therapy.

### **Phase IIa Results**

Antisense's Phase IIa trial results were compared to what can be expected from children at a similar age and also non-ambulant boys treated with corticosteroids as detailed in a paper by Ricotti et al earlier this year. Antisense CEO Mark Diamond said there are at least three other papers showing the expected decline in muscle function with boys on corticosteroid treatment.

The Phase IIa results showed that as measured by a standard MyoPinch test, there was no deterioration on average in the children treated with ATL1102, compared to a 0.38 point drop or 15% loss in pinch strength in boys on corticosteroids for six months.

With grip strength, the boys treated with ATL1102 showed a 0.2 point increase in strength, compared to a 0.5 point drop in those followed in the Ricotti paper or a 10.5% drop.

On the PUL2.0 measure, which assesses upper limb strength, seven of the nine boys either maintained their strength or registered an improvement. The mean gain was 0.9. This compares to another study conducted by Pane *et al* and published last year, in non-ambulant boys at a similar age treated only with corticosteroids, that showed a decline in function over six months of 1.09 points. Once boys with DMD become non-ambulant, a linear deterioration in physical function tends to occur.

*Continued over*

*Bioshares* is published by Blake Industry & Market Analysis Pty Ltd.

Blake Industry & Market Analysis Pty Ltd  
ACN 085 334 292  
PO Box 193  
Richmond Vic 3121  
AFS Licence No. 258032  
Enquiries for *Bioshares*  
Ph: (03) 9326 5382  
Fax: (03) 9329 3350  
Email: info[at]bioshares.com.au

**David Blake - Editor/Analyst**  
Ph: (03) 9326 5382  
Email: david[at]bioshares.com.au

**Mark Pachacz - Editor/Analyst**  
Ph: 0403 850 425  
Email: mark[at]bioshares.com.au

Individual Subscriptions (48 issues/year)  
**\$500** (Inc.GST)  
Edition Number 824 (18 December 2019)

Copyright 2019 Blake Industry and Market Analysis Pty Ltd. ALL RIGHTS RESERVED.  
Secondary electronic transmission, photocopying, reproduction or quotation is strictly prohibited without written consent of the publisher.

– ANP cont'd

There were particularly encouraging results from the level of CD49d+ T cells. As measured by the CD3+ CD49d+ T cells, there was a median 9.78% drop at 24 weeks. Importantly, just four weeks after treatment had stopped, this level increased to a net increase of 9.93% from baseline, which confirms the mechanism of action of this drug candidate.

Professor Thomas Voit, an author on the Ricotti paper, commented on these results that "Disease stabilisation or indeed improvement in function scores in non-ambulant DMD boys is almost unheard of and a very encouraging result."

### Summary

Antisense Therapeutics should continue to attract further interest from investors in the year ahead, given that the company will be moving into a Phase IIb study next year in DMD, a study which may be sufficient for achieving approval in Europe.

The stock will be responsive to the company's confirming the design of the Phase IIb study, receiving regulatory and ethics clearance for the trial, completing manufacture of drug material for the study, and results of discussions with regulatory agencies.

The company retained cash of \$2 million at September 30, 2019, and is expected to receive a tax refund of \$0.55 million this quarter. An underwriting agreement has recently been signed that should see \$5.5 million raised through the exercise of options.

Antisense Therapeutics is capitalised at \$42 million, including the exercise of all outstanding listed options.

### *Milestones for 2020 include:*

- Manufacturing of material for proposed Phase IIb trial (up to 4,000 doses)
- Clinical trial design
- Clinical trial approval and ethics clearance in Europe
- Results of discussions with FDA
- Commencement of Phase IIb study

*Bioshares* recommendation: **Speculative Buy Class B**

**Bioshares**

**How Bioshares Rates Stocks**

For the purpose of valuation, Bioshares divides biotech stocks into two categories. The first group are stocks with existing positive cash flows or close to producing positive cash flows. The second group are stocks without near term positive cash flows, history of losses, or at early stages of commercialisation. In this second group, which are essentially speculative propositions, Bioshares grades them according to relative risk within that group, to better reflect the very large spread of risk within those stocks. For both groups, the rating “Take Some Profits” means that investors may re-weight their holding by selling between 25%-75% of a stock.

**Group A**

Stocks with existing positive cash flows or close to producing positive cash flows.

- Buy** CMP is 20% < Fair Value
- Accumulate** CMP is 10% < Fair Value
- Hold** Value = CMP
- Lighten** CMP is 10% > Fair Value
- Sell** CMP is 20% > Fair Value  
(CMP–Current Market Price)

**Group B**

Stocks without near term positive cash flows, history of losses, or at early stages commercialisation.

**Speculative Buy – Class A**

These stocks will have more than one technology, product or investment in development, with perhaps those same technologies offering multiple opportunities. These features, coupled to the presence of alliances, partnerships and scientific advisory boards, indicate the stock is relative less risky than other biotech stocks.

**Speculative Buy – Class B**

These stocks may have more than one product or opportunity, and may even be close to market. However, they are likely to be lacking in several key areas. For example, their cash position is weak, or management or board may need strengthening.

**Speculative Buy – Class C**

These stocks generally have one product in development and lack many external validation features.

**Speculative Hold – Class A or B or C**

**Sell**

**Corporate Subscribers:** Cogstate, Bionomics, LBT Innovations, Opthea, ResApp Health, Pharmaxis, Dimerix, Adalta, Actinogen Medical, Patrys, Cyclopharm, Emvision, Antisense Therapeutics, Heramed, Imugene, Exopharm, Immutep, Neuroscientific Biopharmaceuticals

**Disclaimer:**

Information contained in this newsletter is not a complete analysis of every material fact respecting any company, industry or security. The opinions and estimates herein expressed represent the current judgement of the publisher and are subject to change. Blake Industry and Market Analysis Pty Ltd (BIMA) and any of their associates, officers or staff may have interests in securities referred to herein (Corporations Law s.849). Details contained herein have been prepared for general circulation and do not have regard to any person’s or company’s investment objectives, financial situation and particular needs. Accordingly, no recipients should rely on any recommendation (whether express or implied) contained in this document without consulting their investment adviser (Corporations Law s.851). The persons involved in or responsible for the preparation and publication of this report believe the information herein is accurate but no warranty of accuracy is given and persons seeking to rely on information provided herein should make their own independent enquiries. Details contained herein have been issued on the basis they are only for the particular person or company to whom they have been provided by Blake Industry and Market Analysis Pty Ltd. The Directors and/or associates declare interests in the following ASX Healthcare and Biotechnology sector securities: Analyst DB: ACR,ADR,CGS,COH,CSL,CYC,MX1,NAN,OPT,SOM,TLX Analyst MP: ACR,CGS,OPT,CUV,MX1,PXS,RNO,SOM. These interests can change at any time and are not additional recommendations. Holdings in stocks valued at less than \$100 are not disclosed.

**Subscription Rates (inc. GST)**

48 issues per year (electronic distribution): **\$500**

For multiple email distributions within \$800 2-3 email addresses  
 the same business cost centre, our \$1100 4-5 email addresses  
 pricing structure is as follows: \$1370 6-10 email addresses

To subscribe, post/fax this subscription form to:

**Bioshares**  
**PO Box 193 Richmond VIC 3121**  
**Fax: +61 3 9329 3350**

I enclose a cheque for \$ \_\_\_\_\_ made payable to **Blake Industry & Market Analysis Pty Ltd**, or

Please charge my credit card \$ \_\_\_\_\_ MasterCard  Visa

Card Number

Signature \_\_\_\_\_ Expiry date \_\_\_\_\_

**Subscriber details**

Name \_\_\_\_\_

Organisation \_\_\_\_\_

Ph ( ) \_\_\_\_\_

Emails \_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_